Frankfurt
13.03.26 | 08:02
0,468 Euro
0,00 % 0,000
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | Egetis Therapeutics: Egetis Receives Notice of Allowance for MCT8 Deficiency Composition Patent in the U.S. | 305 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / March 9, 2026 / Egetis Therapeutics AB (publ) ("Egetis" or the "Company") (NASDAQ Stockholm:EGTX) today announced that the United States Patent and Trademark Office... ► Artikel lesen | |
| EGETIS THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 02.03. | Egetis Therapeutics Launches Educational Websites on MCT8 Deficiency for Physicians and Caregivers | 245 | ACCESS Newswire | STOCKHOLM, SWEDEN / ACCESS Newswire / March 2, 2026 / Egetis Therapeutics AB (publ) ("Egetis" or the "Company") (NASDAQ Stockholm:EGTX), today announced the launch of two updated educational websites... ► Artikel lesen | |
| 26.02. | Egetis Therapeutics AB: Year-End Report January-December 2025 | 127 | GlobeNewswire (Europe) | Egetis submitted the U.S. NDA for Emcitate® (tiratricol) for treatment of MCT8 deficiency· Emcitate® revenue during 2025 amounted to MSEK 62.3, a 40 % increase in constant exchange rates from... ► Artikel lesen | |
| 16.02. | Egetis Therapeutics AB: Egetis provides update on progress with the development of Emcitate (tiratricol) for MCT8 deficiency in Japan | 172 | GlobeNewswire (Europe) | Stockholm, Sweden, February 16, 2026. Egetis Therapeutics AB (publ) ("Egetis" or the "Company") (NASDAQ Stockholm: EGTX), today announced that its Japanese partner Fujimoto Pharmaceuticals, who has... ► Artikel lesen | |
| 04.02. | Egetis Therapeutics AB: FDA's rare pediatric disease priority review program extended until 2029 | 184 | GlobeNewswire (Europe) | Stockholm, Sweden, February 4, 2026. Egetis Therapeutics AB (publ) ("Egetis" or the "Company") (NASDAQ Stockholm: EGTX), today noted that the U.S. Food and Drug Administration's (FDA's) Rare Pediatric... ► Artikel lesen | |
| 29.01. | Egetis Therapeutics AB: Egetis Completes the U.S. Rolling NDA Submission for Emcitate (tiratricol) for Treatment of MCT8 Deficiency | 130 | GlobeNewswire (Europe) | Priority Review and Rare Pediatric Disease Priority Review Voucher requestedAnticipated regulatory decision in September 2026Emcitate® (tiratricol) U.S. launch expected in Q4 2026, if approvedStockholm... ► Artikel lesen | |
| 19.12.25 | Egetis Therapeutics AB: Egetis Therapeutics initiates New Drug Application in the USA for Emcitate (tiratricol) for MCT8 deficiency | 230 | GlobeNewswire (Europe) | Stockholm, Sweden, December 19, 2025. Egetis Therapeutics AB (publ) ("Egetis" or the "Company") (NASDAQ Stockholm: EGTX), today announced that the Company has initiated a rolling New Drug Application... ► Artikel lesen | |
| 10.12.25 | Egetis Therapeutics AB: Egetis and Er-Kim Expand Partnership to Broaden Access to Emcitate Across Central, Eastern, and Southeastern Europe | 153 | GlobeNewswire (Europe) | Stockholm, Sweden, December 10, 2025. Egetis Therapeutics AB (publ) ("Egetis" or the "Company") (NASDAQ Stockholm: EGTX), today announced that the Company, through its wholly-owned subsidiary Rare Thyroid... ► Artikel lesen | |
| 25.11.25 | Egetis-Aktie unter Druck: Positive Studiendaten können Kursverlust nach Q3-Zahlen nicht verhindern | 4 | Investing.com Deutsch | ||
| 25.11.25 | Egetis Therapeutics AB: Interim report Q3 2025 | 178 | GlobeNewswire (Europe) | Egetis to commence a rolling NDA submission in December as granted by the FDA for Emcitate® (tiratricol)· Egetis received FDA Breakthrough Therapy Designation for Emcitate® (tiratricol) for... ► Artikel lesen | |
| 14.11.25 | Egetis Therapeutics AB: Egetis announces positive results from the ReTRIACt study of Emcitate (tiratricol) in MCT8 deficiency | 146 | GlobeNewswire (Europe) | Positive topline results demonstrate a statistically significant (p=0.034) difference in the rate of change in serum T3 in patients randomized to withdrawal (placebo) vs. in patients continuing therapy... ► Artikel lesen | |
| 23.10.25 | Egetis Therapeutics AB: Egetis granted a rolling NDA review by FDA for Emcitate (tiratricol) based on currently available clinical data | 237 | GlobeNewswire (Europe) | The outcomes of a successful pre-NDA meeting with the FDA are:
As agreed with the FDA, the rolling NDA submission will commence in December 2025, targeting a complete NDA submission in early 2026 and... ► Artikel lesen | |
| 02.10.25 | Egetis Therapeutics AB: Egetis Therapeutics intends to carry out a directed share issue of up to 10 percent of outstanding ordinary shares | 198 | GlobeNewswire (Europe) | NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, HONG KONG, ISRAEL, JAPAN, NEW ZEALAND, SOUTH AFRICA... ► Artikel lesen | |
| 21.08.25 | Egetis Therapeutics AB: Interim report Q2 2025 | 250 | GlobeNewswire (Europe) | Egetis reports progress towards US NDA submission for tiratricol· FDA awarded tiratricol Breakthrough Therapy Designation (BTD) in July 2025, based on the Agency's review of Egetis' analysis... ► Artikel lesen | |
| 18.08.25 | Egetis Therapeutics AB: Egetis reports progress towards US NDA submission for tiratricol | 527 | GlobeNewswire (Europe) | FDA awarded tiratricol Breakthrough Therapy Designation (BTD) in July 2025, based on the Agency's review of Egetis' analysis of the survival data set from the international real-world cohort study by... ► Artikel lesen | |
| 15.07.25 | Egetis Therapeutics AB: Egetis receives FDA Breakthrough Therapy Designation for tiratricol for MCT8 deficiency | 359 | GlobeNewswire (Europe) | Stockholm, Sweden, July 15, 2025. Egetis Therapeutics AB (publ) ("Egetis" or the "Company") (NASDAQ Stockholm: EGTX), today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough... ► Artikel lesen | |
| 05.05.25 | Egetis Therapeutics AB: Egetis Confirms Launch of Emcitate in Germany | 533 | GlobeNewswire (Europe) | For investors and media only
Stockholm, Sweden, May 5, 2025. Egetis Therapeutics AB (publ) ("Egetis" or the "Company") (NASDAQ Stockholm: EGTX), a pharmaceutical company dedicated to developing therapies... ► Artikel lesen | |
| 30.04.25 | Egetis Therapeutics AB: Interim report Q1 2025 | 227 | GlobeNewswire (Europe) | Egetis plans to launch Emcitate® in the first country, Germany, on May 1, 2025The European Commission approved Emcitate® (tiratricol) as the first and only treatment for patients with MCT8 deficiency.In... ► Artikel lesen |
18 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SANOFI | 76,22 | +0,03 % | EMA Panel Backs Moderna's COVID-Flu Shot, Sanofi's Sleeping Sickness Drug, Ipsen's Cancer Drug | PARIS (dpa-AFX) - At its February 2026 meeting, the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted positive opinions for Moderna's combined COVID-19... ► Artikel lesen | |
| GSK | 23,630 | +0,51 % | GSK verkauft Rechte an Arzneikandidat für bis zu 690 Mio Dollar | DJ GSK verkauft Rechte an Arzneikandidat für bis zu 690 Mio Dollar
Von Adria Calatayud
DOW JONES--GSK verkauft die Rechte an dem Medikamentenkandidaten Linerixibat an das italienische Pharmaunternehmen... ► Artikel lesen | |
| ASTRAZENECA | 167,15 | -0,03 % | JEFFERIES stuft ASTRAZENECA auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat das Kursziel für Astrazeneca von 15000 auf 18000 Pence angehoben und die Einstufung auf "Buy" belassen. Die Briten seien der einzige europäische... ► Artikel lesen | |
| TILRAY BRANDS | 6,050 | 0,00 % | Tilray Brands, Inc.: Tilray Medical, CC Pharma und 14U Pharma geben strategische Allianz mit der "gesund leben"-Kooperation und Alliance Healthcare Deutschland bekannt, um die Marktexpansion zu beschleunigen und den Zugang zu Apotheken in ganz Deutschland | DENSBORN, Deutschland, March 12, 2026 (GLOBE NEWSWIRE) -- Tilray Pharma, die Pharmasparte von Tilray Brands, Inc. (Nasdaq: TLRY; TSX: TLRY), hat eine strategische Partnerschaft mit Tilray Medical, CC... ► Artikel lesen | |
| DERMAPHARM | 40,700 | -0,12 % | Dermapharm Holding SE: Vorläufer bestätigen Margenfokus trotz Umsatzrückgang; KAUFEN. | Vorläufige Ergebnisse für das Geschäftsjahr 2025 von Dermapharm Holding (DMP) zeigen einen Umsatzrückgang von 1,3 % auf 1.165 Mio. EUR, was leicht unter den Erwartungen liegt, jedoch innerhalb der Prognose... ► Artikel lesen | |
| QUANTUM BIOPHARMA | 2,120 | -4,50 % | Quantum BioPharma Provides Corporate Update | THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FORDISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES. TORONTO, March 10, 2026... ► Artikel lesen | |
| TONIX PHARMACEUTICALS | 12,000 | +2,56 % | Tonix Pharmaceuticals Holding Corp.: Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights | TONMYA (cyclobenzaprine HCl sublingual tablets) launched November 17, 2025, for the treatment of fibromyalgia; through February 27, 2026, more than 1,500 healthcare providers have prescribed TONMYA... ► Artikel lesen | |
| FILANA THERAPEUTICS | 1,750 | +2,52 % | Cassava Sciences Announces Name Change to Filana Therapeutics, Inc. | New corporate identity reflects the Company's mission to develop novel medicines to modulate filamin A and address unmet needs in treating TSC-related epilepsy Filana Therapeutics to begin trading... ► Artikel lesen | |
| OPKO HEALTH | 1,025 | +1,28 % | OPKO Health, Inc.: OPKO Health Reports Fourth Quarter 2025 Business Highlights and Financial Results | MIAMI, Feb. 26, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) (OPKO) reports business highlights and financial results for the three and 12 months ended December 31, 2025, and introduces... ► Artikel lesen | |
| SELLAS LIFE SCIENCES | 4,280 | -1,95 % | SELLAS Life Sciences Group, Inc.: SELLAS Life Sciences Announces Enrollment of First Patient in Newly Diagnosed First-Line AML Trial of SLS009 | - Study to Enroll 80 Patients Unlikely to Benefit from Venetoclax/Azacitide (Aza/Ven) Therapy in the US and Europe -- SELLAS' Predictive Biomarker and AI Assisted Precision Medicine Models to be Utilized... ► Artikel lesen | |
| SOLIGENIX | 1,220 | 0,00 % | SOLIGENIX, INC.: Positive Clinical Results from Phase 2 Trial of SGX945 for the Treatment of Behçet's Disease Published in Rheumatology (Oxford) | Study results support advancing SGX945 in this difficult-to-treat orphan disease
Results suggest potential durability of response for maintenance therapy
PRINCETON, N.J., Dec. 18... ► Artikel lesen | |
| BETTERLIFE PHARMA | 0,038 | -2,60 % | BetterLife Pharma Inc.: BetterLife Pharma to Participate in YAFO Capital Access Asia Partnering Forum During JPM Week in San Francisco | Vancouver, British Columbia--(Newsfile Corp. - January 6, 2026) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company"), an emerging biopharmaceutical company... ► Artikel lesen | |
| THERIVA BIOLOGICS | 0,178 | 0,00 % | Theriva Biologics, Inc.: Theriva Biologics Reports Full-Year 2025 Operational Highlights and Financial Results | - Advancing clinical development of VCN-01 for pancreatic ductal adenocarcinoma and retinoblastoma -
- Licensed SYN-020 to Rasayana Therapeutics for development in multiple indications; up to $38... ► Artikel lesen | |
| NOVABAY PHARMACEUTICALS | 1,260 | 0,00 % | NovaBay Pharmaceuticals: Aktionäre geben grünes Licht für Satzungsänderungen und Aktienausgabe | ||
| BAYER | 38,845 | -0,73 % | SHORT SQUEEZE bei Gerresheimer? WACHSEN Bayer und MustGrow bald gemeinsam? | Während die Börse den Iran-Krieg und steigende Energiepreise verdauen, zieht plötzlich die Aktie von Gerresheimer spürbar an. News gibt es keine. Ist ein Short Squeeze möglich? Leerverkäufer hatten... ► Artikel lesen |
Das Unternehmen EGETIS THERAPEUTICS AB kann der Branche Pharma zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 0,468 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu EGETIS THERAPEUTICS AB finden Sie auf Wallstreet Online.